Fri, Dec 19, 2014, 7:45 AM EST - U.S. Markets open in 1 hr 45 mins


% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

dragan7777777777 205 posts  |  Last Activity: 16 hours ago Member since: Apr 20, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Where is the beef?!.......

    by dragan7777777777 19 hours ago
    dragan7777777777 dragan7777777777 16 hours ago Flag

    Sure, where is the money? They are having bombastic PRs and promises for quite some time, and on the end: WHERE IS THE MONEY?.........

  • dragan7777777777 by dragan7777777777 19 hours ago Flag

    Market way up/green and ANY got another "great news" ( meaning another empty, pumping PR ) and stock is down. Where is the beef?. This is a scam........

  • Exact Sciences (EXAS) PT Raised to $32 at Goldman Sachs

    December 18, 2014 6:56 AM EST Goldman Sachs reiterated a Buy rating and raised its 6-month price target on Exact Sciences (NASDAQ: EXAS) to $32.00 (from ....

  • Reply to

    A quick question for the board.....

    by diejour_44 Dec 17, 2014 10:06 AM
    dragan7777777777 dragan7777777777 Dec 17, 2014 10:31 AM Flag

    Very simple answer, shorty. You buy 4M shares at 25.75 because you know some good news is coming soon and your stock will go to 35.75. But, if you try to buy now 4M shares at current price, let's say at 25, then you will move price right way to 35.75 and that is not what you want to pay to get 4M shares. You got it?......

  • dragan7777777777 by dragan7777777777 Dec 17, 2014 6:06 AM Flag

    There a is a wild rumor that EXAS might buyout SQNM. That would be the answer why EXAS just raised 100M in 4M shares offering. SQNM just forged strong collaboration with ILMN. ILMN paying SQNM upfront 50M. From fundamental point of view this make sense. EXAS and SQNM are both in genetic diagnostics tests. Also, there is one step above, ILMN might be interested to buy this new entity ( EXAS + SQNM ) because ILMN is getting very interested in genetic diagnostics. This is very wild rumor and very long shot, but not unreasonable one.....

  • Reply to

    50 Million People in Medicare x $502

    by scorekeeper101a Dec 13, 2014 6:39 PM
    dragan7777777777 dragan7777777777 Dec 14, 2014 3:03 PM Flag

    Plus other tangibles: IP, pipelines/possible other cancer screening tests and reasonable possibility of buyout with significant premium. Add another 20$....

  • Reply to

    $6 is a great entry point

    by risicare Dec 12, 2014 1:00 PM
    dragan7777777777 dragan7777777777 Dec 12, 2014 4:47 PM Flag

    You must be kidding!? 100M revenue, 1B market cap! What are you smoking?....

  • Reply to

    so they "delisted"..

    by marsh1482 Dec 11, 2014 7:34 PM
    dragan7777777777 dragan7777777777 Dec 12, 2014 11:43 AM Flag

    Pumping want do, junk is junk....

  • Reply to

    so they "delisted"..

    by marsh1482 Dec 11, 2014 7:34 PM
    dragan7777777777 dragan7777777777 Dec 12, 2014 6:25 AM Flag

    Plain and simple. This is a scam. Pumped up and hyped up. Retail investors will never see any money. All PRs and Dell, Google, Yahoo and so on "deals" are smoke and mirrors. Too bad no shares available to short....

  • Reply to

    dream on

    by marsh1482 Dec 11, 2014 1:49 PM
    dragan7777777777 dragan7777777777 Dec 11, 2014 1:57 PM Flag

    Hey, that is my line. Too bad no shares to short....

  • Reply to

    Muddy Waters?

    by emmajohn855 Dec 11, 2014 12:02 PM
    dragan7777777777 dragan7777777777 Dec 11, 2014 12:19 PM Flag

    No, they are busy looking at BABA, and looking behind their backs.......

  • dragan7777777777 by dragan7777777777 Dec 10, 2014 2:39 PM Flag

    Too bad no shares to short....

  • Reply to

    Still a lot of shares short to cover.

    by muy_loco_2000 Dec 10, 2014 10:29 AM
    dragan7777777777 dragan7777777777 Dec 10, 2014 11:00 AM Flag

    Next stop at 200 days MA, 17.09.......

  • dragan7777777777 by dragan7777777777 Dec 10, 2014 9:59 AM Flag

    Good news leak? I hope no buyout offer at this price.....

  • Reply to

    Quiet period expires Tuesday, 12.9

    by inquiries8788 Dec 8, 2014 9:02 PM
    dragan7777777777 dragan7777777777 Dec 8, 2014 10:08 PM Flag

    Upgrades coming in.....

  • Reply to

    A message worth repeating here

    by commoncentsinvestor Dec 7, 2014 12:38 PM
    dragan7777777777 dragan7777777777 Dec 8, 2014 6:08 AM Flag

    -Weekly or biweekly bombastic, empty PRs aiming at retail investors, not bringing any money to the bottom line
    -They should start making money yesterday, or ship will sink to the bottom line
    - Why there are no buyout offers for revolutionary, disruptive technology at this "bottom" low price....
    - Bottom line: this is well crafted smoke and mirrors pump. Merry Christmas to IHUB gang....

  • dragan7777777777 by dragan7777777777 Dec 6, 2014 3:20 PM Flag

    Well, glass half empty or half full. Colonoscopy is probably the best screening tool for high risk patients ( multiple polyps, adenomatosis, colon cancer family history ). ColoGuard will become med standard for "low risk" screening. I am anesthesiologist ( 40 yrs practice ), and I have seen a number or bowel perforation and at least two deaths.

    One patient died during emergency surgery ( laparotomy ) and the other died post-op from complications, septic shock. True, both patients were old and had some health issues. But, no invasive procedure with or without anesthesia is safe. Healthy Joan Rivers died from IV sedation and "low risk" out-patient procedure. There will be no deaths from ColoGuard. Period. Scope doctors ( GI ) would like to protect their business and they tell us how safe is colonoscopy. As I tell to med students "the best surgery is no surgery and the best anesthesia is no anesthesia"......

  • dragan7777777777 by dragan7777777777 Dec 6, 2014 10:24 AM Flag

    Bottom line: colonoscopies are not more accurate that Cologuard, plus extremely unpleasant procedure and there are significant risks, like bleeding,
    bowel perforation ( meaning emergency bowel surgey, laparotomy ), anesthesia complications, even deaths. ColoGuard will cut the number of colonoscopies as a first line screening procedure, but colonoscopies will not be eliminated, unfortunately in spite of all risks......

  • dragan7777777777 by dragan7777777777 Dec 6, 2014 10:16 AM Flag

    Colonoscopies are considered the gold standard for colon cancer screening.

    MedPage Today reports a recent study from the Annals of Internal Medicine, that suggests it’s much less accurate than initially thought. The problem was with detecting right-sided cancers, where “the test missed just about every cancer in the right side of the colon, where cancers are harder to detect but about 40 percent arise. And it also missed roughly a third of cancers in the left side of the colon.”

    Instead of the 90+ percent improvement in mortality rate that’s commonly quoted, the authors suggest the number is closer to 60 percent to 70 percent.

    That’s a surprising finding, and needs to be validated by future studies. If true, how will it change current recommendations? Will colonoscopies be recommended to be performed more frequently? Should fecal occult stool cards be performed in between colonoscopies? Will this affect the role of virtual colonoscopies?

  • dragan7777777777 by dragan7777777777 Dec 6, 2014 10:14 AM Flag

    "Highly Accurate At-Home Colon Cancer Test Approved
    DNA analysis of stool boosts accuracy rate of Cologuard to more than 90 percent, researchers say"

    HealthDay Reporter

    MONDAY, Aug. 11, 2014 (HealthDay News) -- The U.S. Food and Drug Administration on Monday approved a new at-home, DNA-based stool test that screens for colorectal cancer with more than 90 percent accuracy.

    The decision was based on an FDA panel's unanimous decision in March that the benefits of Exact Sciences Corp.'s Cologuard test outweighed its risks.

    "This approval offers patients and physicians another option to screen for colorectal cancer," Alberto Gutierrez, director of the Office of In Vitro Diagnostics and Radiological Health at the FDA's Center for Devices and Radiological Health, said in an agency news release.

    Last year, nearly 143,000 new cases of colorectal cancer were diagnosed in the United States and almost 50,000 Americans died of the disease, according to the U.S. National Cancer Institute.

    A study published in March in the New England Journal of Medicine found Cologuard had a very high accuracy rate in spotting colon cancer.

31.44+0.27(+0.87%)Dec 18 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.